An interventional study of Robotic-assisted bronchoscopy under propofol in Lung Lesions, Robotic Assisted Bronchoscopy and Propofol, sponsored by University of Zurich. Terminated at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by University of Zurich · Not applicable, Interventional, and Diagnostic
In this study, the investigators want to find out whether robot-assisted bronchoscopy also works with moderate sedation (Propofol), as is already used in standard bronchoscopies. The study is being conducted as a pilot study. This means that it is an initial test run for a scientific investigation. The investigators are testing on a small scale whether the intervention works as predicted before a larger study is conducted.
University of Zurich is the lead sponsor of 1,030 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: Robotic-assisted bronchoscopy under propofol
In this study, patients will undergo a robotic-assisted bronchoscopy under moderate sedation with propofol. While the use of propofol as a sedative is common for manual bronchoscopies, robotic-assisted bronchoscopy is only permitted under general anesthesia. In the study intervention, the investigators want to test the feasibility of the combination of robotic-assisted bronchoscopy under propofol.
Confirmation of tool-in-lesion
Composite outcome defined as meeting at least one of the following criteria: 1) Radiological confirmation of the biopsy tool located within the target lung lesion using cone-beam CT. 2) Positive signal on radial endobronchial ultrasound (rEBUS) indicating the lesion was reached. 3) Pathological confirmation of specific malignant or benign tissue in the biopsy sample.
Time frame: during the intervention
Acquisition of at least one histological sample
Time frame: during the intervention
histopathological classification of the pulmonary lesion
Time frame: From enrollment to the end of treatment at 8 days.
Procedure duration
Time frame: during the intervention
Diagnostic yield of biopsies
According to the ATS2024 strict consensus criteria (https://doi.org/10.1164/rccm.202401-0192ST)
Time frame: From enrollment to the end of treatment at 8 days.
diagnostic accuracy for malignancy
Biopsies with definitive malignancy/Cases with proven malignance over the course of 3 months
Time frame: From enrollment to the end of treatment of 3 months
cost analysis
Total billed costs in CHF for the bronchoscopy excl. anesthesia
Time frame: From enrollment to the end of treatment at 8 days.
Safety profile
Rate of pneumothoraces, bleeding rates (Nashville Classification Grad \>2), and rate of unplanned hospitalizations \>5 days.
Time frame: From enrollment to the end of treatment at 8 days.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Zurich